CRIXIVAN - MSD Responsibility

Worldwide Marketing Authorization Status: CRIXIVAN® (indinavir sulfate) Indication: HIV infection MK-0639: 100mg, 200mg, and 400mg Number

Country Australia Austria Belgium Bulgaria

Approval Date 06-Mar-1998 4-Oct-1996 4-Oct-1996 4-Oct-1996

Canada Chile China Croatia Cyprus Czech Republic

13-Sep-1996 17-Jan-1997 18-Dec-1998 4-Oct-1996 4-Oct-1996 4-Oct-1996

Denmark Estonia Finland France Germany Greece

4-Oct-1996 4-Oct-1996 4-Oct-1996 4-Oct-1996 4-Oct-1996 4-Oct-1996

22 23 24 25 26 27 28

Hong Kong Hungary Iceland Ireland Italy Japan

27-Sep-1996 4-Oct-1996 4-Oct-1996 4-Oct-1996 4-Oct-1996 28-Mar-1997

Korea, Republic of Latvia Lebanon Lithuania Luxembourg Malta

20-Nov-2001 4-Oct-1996 28-May-1997 4-Oct-1996 4-Oct-1996 4-Oct-1996

29 30 31 32 33 34

Mauritania Namibia Netherlands New Zealand Norway Poland

30-Jun-2003 18-Aug-2004 4-Oct-1996 25-Feb-1999 4-Oct-1996 4-Oct-1996

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

35 36 37 38

Portugal Romania Singapore Slovakia

4-Oct-1996 4-Oct-1996 3-Jun-1996 4-Oct-1996

39 40 41 42 43 44

Slovenia South Africa Spain Sweden Switzerland United Kingdom

4-Oct-1996 31-Oct-1996 4-Oct-1996 4-Oct-1996 25-Jul-1996 4-Oct-1996

45

United States

13-Mar-1996

June 2016